Academic Editor: Michael H. Dahan
Background: The relationship between oral contraceptive (OC) use and breast
cancer risk is highly debated. Recent publications support a slight increase in
overall breast cancer risk among OC user women, in particular among the current
users. Women with inherited BRCA1 (Breast cancer type 1) or
BRCA2 (Breast cancer type 2) gene mutations are at increased risk of
breast and ovarian cancers, which is often mistakenly attributed to their
elevated endogenous estrogen levels. The aim of presented meta-analysis was to
assess the effects of OC use on breast cancer risk in BRCA mutation
carrier women with minimal bias. Methods: A systematic search strategy was used
to identify relevant studies, Stata (version 15) was used for meta-analysis.
Results: Individual datasets from 13 studies totaling 20,202 patients were
analyzed. The combined results showed no significant increase in risk of breast
cancer in BRCA mutation carriers who had ever used oral contraceptive
(HR = 1.09, 95% CI: 0.71–1.69 among BRCA1 mutation carriers and HR =
1.19, 95% CI: 0.73–1.95 among BRCA2 mutation carriers, respectively).
However, in correlation with long-term (